Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade immunotherapy) combined with chemotherapy based on the patients risk status to get the patient into the best response possible. Then patients will receive lower doses of chemoimmunotherapy and allogeneic stem cell transplantation (stem cells from another person). The investigators this this new treatment will improve survival rates in this high-risk population of patients.

NCT Number	NCT07013565
Lead Sponsor	New York Medical College Collaborators: University of Alabama at Birmingham, Helen DeVos Children's Hospital, Nationwide Children's Hospital, Memorial Sloan Kettering Cancer Center, University of Utah, Ohio State University, University of North Carolina, Children's Hospital of Philadelphia, Medical College of Wisconsin, Children's Hospital of Orange County
Conditions	Anaplastic Large Cell Lymphoma, ALK-Positive
Enrollment	20 participants
Start Date	2025-08-07
Primary Completion	2029-07-01 (estimated)
Study Completion	2030-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-20